The NATO Innovation Fund (NIF) made its first investment in a startup of biotechnology. The VC ARM of the Allianz today announced that it is leading a 35 million dollar series per round for the Biotech portal based in Great Britain to strengthen NATO defense against biological warfare.
Portal develops portal, diagnostic devices operated with AI that can recognize pathogens on the level with single molecules. In contrast to conventional laboratory-based systems, its platform is designed for the provision of field advisors. The aim is to offer a quick identification of biological threats on site.
Ana Bernardo-Gancedo, Senior Associate at NATO Innovation Fund, told Reuters that this ability for defense and security is of crucial importance. “We believe that it is absolutely necessary that we can recognize, monitor and create countermeasures,” she said.
Set up in 2022 In response to the full invasion of Ukraine in Russia in Ukraine, NATO Innovation Fund has over 1 billion USD to over 1 billion USD Invest in two usage technologiesincluding AI, space and energy intelligibility. The move to biotechnology reflects growing concerns regarding the security effects of synthetic biology and potential biowarkie. These worries have intensified since the Covid 19 pandemic vulnerable Companies relate to biological threats, whether on purpose or not.
Andy Heron, CEO of Portal, said that the company's sensors could be used for continuous environmental surveillance that extends from open fields to municipal water supply. “It not only enables them to recognize what they knew, but also enable them to recognize what they didn't know,” Heron told Reuters.
The 💜 the EU technology
The latest rumors from the EU -Tech scene, a story of our wise old founder Boris and some questionable KI art. It is free of charge every week in your inbox. Register now!
The investment follows an 8 million. -Dollar contract, which was awarded last week by the US Defense Advanced Research Projects Agency (Darpa) to Portal. The deal will finance the development of a portable device to load therapeutic freight in red blood cells and enable field -based, personalized cell therapies in remote environments.
Portal was founded in 2023 and launched three product lines and signed over 50 commercial partnerships, according to the company. In addition to defense applications, double technology could also help the discovery and medicine of drugs by enabling scientists to quickly identify and characterize proteins.
NIF led the investment of Serie A together with the Earlybird Venture Capital, based in Berlin. The round also saw the participation of SCVC, Pillar VC, 8VC, Amino Collective, Outgry, WE Venture Capital, British Business Bank and Wilson Sons Venture ARM WS Investment Company.
Comments are closed.